Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss
Jazyk angličtina Země Švýcarsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
28027898
DOI
10.1016/j.pan.2016.12.004
PII: S1424-3903(16)31251-0
Knihovny.cz E-zdroje
- Klíčová slova
- Diabetes mellitus, Glucose-dependent insulinotropic peptide, Pancreatic ductal adenocarcinoma, Pancreatic polypeptide,
- MeSH
- biologické markery krev MeSH
- diabetes mellitus 2. typu krev komplikace patofyziologie MeSH
- dospělí MeSH
- duktální karcinom pankreatu krev komplikace diagnóza patofyziologie MeSH
- glukagonu podobný peptid 1 krev MeSH
- hmotnostní úbytek * MeSH
- krevní glukóza metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory slinivky břišní krev komplikace diagnóza patofyziologie MeSH
- neuropeptid Y krev MeSH
- pankreatický polypeptid krev MeSH
- peptid YY krev MeSH
- porucha glukózové tolerance krev komplikace patofyziologie MeSH
- senioři MeSH
- studie případů a kontrol MeSH
- žaludeční inhibiční polypeptid krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- biologické markery MeSH
- glukagonu podobný peptid 1 MeSH
- krevní glukóza MeSH
- neuropeptid Y MeSH
- pankreatický polypeptid MeSH
- peptid YY MeSH
- žaludeční inhibiční polypeptid MeSH
BACKGROUND: The changes in gastrointestinal hormones associated with pancreatic ductal adenocarcinoma (PDAC) in patients with impaired glucoregulation have yet to be evaluated. The aim of this study was to determine plasma concentrations of selected gastrointestinal hormones in PDAC patients with and without diabetes and to compare them with levels found in Type 2 diabetic patients without cancer. METHODS: In this study we examined plasma concentrations of glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), pancreatic polypeptide (PP), peptide YY (PYY) and neuropeptide Y (NPY), and cytokines leptin and adiponectin in 94 patients with histologically confirmed PDAC. Thirty-nine patients with Type 2 diabetes without PDAC and 29 healthy individuals with no evidence of acute or chronic diseases were examined as controls. RESULTS: Significantly lower plasma concentrations of GIP were found in PDAC patients with new-onset diabetes/prediabetes (n = 76), or in those with normal glucose regulation (n = 18), compared to patients with Type 2 diabetes without PDAC and controls (15.5 (3.7-64.5) or 6.5 (1.7-24.5) vs. 39.8 (15.1-104.7) and 28.8 (7.4-112.2) ng/L, p < 0.001); the same relationship was observed for PP (38.9 (10.2-147.9) or 28.1 (7.9-100.0) vs 89.1 (38.0-208.9) and 75.8 (30.1-190.6) ng/L, p < 0.01), respectively. The lowest levels of GIP and PP concentrations were found in PDAC patients with new-onset diabetes/prediabetes and weight loss > 2 kg (p < 0.001). CONCLUSIONS: We conclude that GIP and PP plasma concentrations are lower in pancreatic cancer irrespective of the degree of glucose intolerance as compared to Type 2 diabetic patients and healthy controls. In new onset diabetes especially if associated with weight loss, these changes may represent a new clue for the diagnosis of PDAC.
3rd Department of Internal Medicine and Laboratory for Endocrinology and Metabolism Prague Czechia
Department of Biochemistry and Experimental Oncology Prague Czechia
Citace poskytuje Crossref.org
